APR March 2024 - 2
American Pharmaceutical Review
Published by
POSTMASTER: Send change of addresses to
American Pharmaceutical Review, PO Box 8696
Lowell, MA 01853
CompareNetworks, Inc.
Editorial
EDITOR-IN-CHIEF| Mike Auerbach
mauerbach@comparenetworks.com
WEB CONTENT MANAGER | Douglas Franklin
dfranklin@comparenetworks.com
Sales
ACCOUNT EXECUTIVE| Ashley Poste
aposte@aprpub.com * 650-243-5639
Production
SENIOR ART DIRECTOR | Jennifer Campbell
jcampbell@comparenetworks.com
LAYOUT DESIGNER, TRADE SHOW COORDINATOR
Allison Chelminiak
achelminiak@comparenetworks.com
Corporate
CEO | Paul Gatti, PhD
VP, OPERATIONS & PHARMA GROUP BRAND LEADER
Jeanely Hunt, MS, MBA
American Pharmaceutical Review (ISSN 1099-8012) is published
seven times a year (February, March, April, June, August,
October, December) by CompareNetworks, Inc.
395 Oyster Point Blvd. #300 South San Francisco, CA 94080.
Subscription Rate (7 issues) 1 year $135.00.
Periodicals postage paid at South San Francisco, CA 94080
and additional mailing offices.
395 Oyster Point Blvd. #300
South San Francisco, CA 94080
www.comparenetworks.com
E-mail: info@comparenetworks.com
Website: www.americanpharmaceuticalreview.com
Printed in the USA
Publication Agreement #40739004.
Return undeliverable Canadian addresses to:
IMEX, PO Box 25542, London, ON N6C 6B2, Canada,
Email: info@comparenetworks.com
Copyright rests with the publishers.
All rights reserved ©2024
CompareNetworks, Inc.
No part of this publication may be reproduced, stored in a
retrieval system or transmitted in any form or by any means
electronic, mechanical, photocopying, recording or otherwise
without the prior written permission of the copyright holder.
While the publishers believe that all information contained in
this publication was correct at the time of going to press, they
can accept no liability for any inaccuracies that may appear or
loss suffered directly or indirectly by any reader as a result of
any advertisement, editorial, photographs or other material
published in American Pharmaceutical Review.
Safeguarding Global Health
- with every test we complete.
We are a leading global provider of laboratory testing and
expert advisory services for pharmaceutical companies.
®
Our major Pharmaceutical
testing categories include:
Extractables & Leachables
Biocompatibility
Packaging Validation
Lot Release
Sterilization Validation
Sterility Assurance
Drug Device Combinations
Analytical Chemistry
FDA Registered ISO 17025
Let us perform the necessary
testing to get your product
to market.
Contact our team of experts today.
Sales Europe +32 16 40 04 84 | InfoEurope@Nelsonlabs.com
Sales US +1 801-290-7502 | Sales@NelsonLabs.com
www.NelsonLabs.com
2 |
| March 2024
http://www.comparenetworks.com
http://www.americanpharmaceuticalreview.com
http://www.NelsonLabs.com
APR March 2024
Table of Contents for the Digital Edition of APR March 2024
Message from the Editor
Editorial Advisory Board
BIOPHARMACEUTICALS - Getting to GMP-Quality Biotherapeutics From Today’s Bench-Scale Continuous Manufacturing Systems: A Gap Analysis
MICROBIOLOGY - Critical Behavioral Attributes and the Application of COM-B Framework in Aseptic Processing
FORMULATION AND DEVELOPMENT - Use of AUC in AAV Analysis in a GMP Setting
FORMULATION AND DEVELOPMENT - Precision Medicine in Clinical Trials: A Statistical Perspective
An Interview with Dan Smithey, PhD President & CEO, Serán
FORMULATION AND DEVELOPMENT - Still Early Days for AI in Drug Discovery...Says Who?
QC Corner - Enhancing Material and Equipment Availability in Production Isolators
BIOPHARMACEUTICALS - Technologies for Aseptic Filling: The Choice is Clear
Vendor Viewpoint - Data Integrity and Rapid Micro Methods: Transforming to a Modern Microbiology Lab
MICROBIOLOGY - Bacterial Spore Formers in Disinfectant Efficacy Testing
Partner Perspective - Nanoparticle Technologies: Enablers for Ocular Drug Delivery
DRUG DELIVERY - Your Nails and You
DRUG DEVELOPMENT - Battling Exorbitance: High Costs in Sickle Cell Gene Therapies and the Imperative of Global Patient Registries for Equity
FORMULATION AND DEVELOPMENT - How Pharma Companies Are Solving Regulatory Challenges with AI-based Technology
Event Preview - CPHI North America
Event Preview - Excipient World 2024
P.I.N. Points
Advertiser's Index
APR March 2024 - CoverTip01
APR March 2024 - CoverTip02
APR March 2024 - Cover1
APR March 2024 - Cover2
APR March 2024 - 1
APR March 2024 - 2
APR March 2024 - 3
APR March 2024 - 4
APR March 2024 - 5
APR March 2024 - Message from the Editor
APR March 2024 - Editorial Advisory Board
APR March 2024 - BIOPHARMACEUTICALS - Getting to GMP-Quality Biotherapeutics From Today’s Bench-Scale Continuous Manufacturing Systems: A Gap Analysis
APR March 2024 - 9
APR March 2024 - 10
APR March 2024 - 11
APR March 2024 - 12
APR March 2024 - 13
APR March 2024 - MICROBIOLOGY - Critical Behavioral Attributes and the Application of COM-B Framework in Aseptic Processing
APR March 2024 - 15
APR March 2024 - 16
APR March 2024 - 17
APR March 2024 - 18
APR March 2024 - FORMULATION AND DEVELOPMENT - Use of AUC in AAV Analysis in a GMP Setting
APR March 2024 - 20
APR March 2024 - 21
APR March 2024 - 22
APR March 2024 - 23
APR March 2024 - FORMULATION AND DEVELOPMENT - Precision Medicine in Clinical Trials: A Statistical Perspective
APR March 2024 - 25
APR March 2024 - 26
APR March 2024 - 27
APR March 2024 - An Interview with Dan Smithey, PhD President & CEO, Serán
APR March 2024 - 29
APR March 2024 - 30
APR March 2024 - FORMULATION AND DEVELOPMENT - Still Early Days for AI in Drug Discovery...Says Who?
APR March 2024 - 32
APR March 2024 - 33
APR March 2024 - QC Corner - Enhancing Material and Equipment Availability in Production Isolators
APR March 2024 - 35
APR March 2024 - BIOPHARMACEUTICALS - Technologies for Aseptic Filling: The Choice is Clear
APR March 2024 - 37
APR March 2024 - 38
APR March 2024 - 39
APR March 2024 - Vendor Viewpoint - Data Integrity and Rapid Micro Methods: Transforming to a Modern Microbiology Lab
APR March 2024 - 41
APR March 2024 - MICROBIOLOGY - Bacterial Spore Formers in Disinfectant Efficacy Testing
APR March 2024 - 43
APR March 2024 - Partner Perspective - Nanoparticle Technologies: Enablers for Ocular Drug Delivery
APR March 2024 - 45
APR March 2024 - 46
APR March 2024 - 47
APR March 2024 - DRUG DELIVERY - Your Nails and You
APR March 2024 - 49
APR March 2024 - 50
APR March 2024 - 51
APR March 2024 - DRUG DEVELOPMENT - Battling Exorbitance: High Costs in Sickle Cell Gene Therapies and the Imperative of Global Patient Registries for Equity
APR March 2024 - 53
APR March 2024 - 54
APR March 2024 - 55
APR March 2024 - FORMULATION AND DEVELOPMENT - How Pharma Companies Are Solving Regulatory Challenges with AI-based Technology
APR March 2024 - 57
APR March 2024 - Event Preview - CPHI North America
APR March 2024 - 59
APR March 2024 - Event Preview - Excipient World 2024
APR March 2024 - 61
APR March 2024 - P.I.N. Points
APR March 2024 - 63
APR March 2024 - Advertiser's Index
APR March 2024 - Cover3
APR March 2024 - Cover4
https://www.nxtbookmedia.com